2021
Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Ul Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz CS, Parise H, Lansky A. Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. Contemporary Clinical Trials 2021, 110: 106547. PMID: 34461322, PMCID: PMC8397504, DOI: 10.1016/j.cct.2021.106547.Peer-Reviewed Original ResearchConceptsHospitalized COVID-19 patientsCOVID-19 patientsStandard of careElectronic health recordsComplications TrialSevere COVID-19 diseaseWorld Health Organization (WHO) ordinal scaleVenous thromboembolic eventsHealth recordsCombination of colchicineRates of morbidityCOVID-19 diseaseCost-effective treatmentPrimary endpointRespiratory failureThromboembolic eventsClinical improvementMyocardial injuryPragmatic trialClinical trialsPatientsEvent ascertainmentHealth NetworkRosuvastatinTrials
2019
Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study
Laird JR, Zeller T, Holden A, Scheinert D, Moore E, Mendes R, Schmiedel R, Settlage R, Lansky A, Jaff MR, Investigators B, Elmasri F, Robinson W, Beasley R, Mego D, Marica S, Bersin R, Kujath S, Razavi M, Teßarek J, Schulte K. Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study. Journal Of Vascular And Interventional Radiology 2019, 30: 836-844.e1. PMID: 30956077, DOI: 10.1016/j.jvir.2018.12.031.Peer-Reviewed Original ResearchConceptsMajor adverse eventsWalking Impairment QuestionnaireQuality of lifeLesion revascularizationPrimary patencyMyocardial infarctionIliac artery occlusive diseaseComposite endpoint rateProcedure-related deathsTarget lesion revascularizationArtery occlusive diseaseSingle-arm studyMajor amputationRutherford categoryOcclusive lesionsPrimary endpointSecondary endpointsAdverse eventsClinical improvementImpairment QuestionnaireOcclusive diseaseClinical outcomesMulticenter studyEndpoint rateIliac artery
2011
Initial experience with a dedicated coronary re‐entry device for revascularization of chronic total occlusions
Whitlow PL, Lombardi WL, Araya M, Wyman R, Torres H, Dauvergne C, Tsuchikane E, Lansky A, Thompson CA. Initial experience with a dedicated coronary re‐entry device for revascularization of chronic total occlusions. Catheterization And Cardiovascular Interventions 2011, 80: 807-813. PMID: 22121076, DOI: 10.1002/ccd.23417.Peer-Reviewed Original ResearchConceptsChronic total coronary occlusionsDistal true lumenRe-entry deviceTrue lumenAntegrade guidewireWire entrapmentTIMI 3 flowTotal coronary occlusionChronic total occlusionGuidewire penetrationConsecutive CTO lesionsPrimary endpointProspective registryClinical improvementSuccessful recanalizationCoronary perforationMajor complicationsCTO lesionsCoronary occlusionCTO interventionTotal occlusionLesion characteristicsSubintimal spaceRetrograde techniqueInitial experience
2001
Intravascular Radiation Therapy after Balloon Angioplasty of Narrowed Femoropopliteal Arteries to Prevent Restenosis: Results of the PARIS Feasibility Clinical Trial
Waksman R, Laird J, Jurkovitz C, Lansky A, Gerrits F, Kosinski A, Murrah N, Weintraub W, Investigators F. Intravascular Radiation Therapy after Balloon Angioplasty of Narrowed Femoropopliteal Arteries to Prevent Restenosis: Results of the PARIS Feasibility Clinical Trial. Journal Of Vascular And Interventional Radiology 2001, 12: 915-921. PMID: 11487671, DOI: 10.1016/s1051-0443(07)61569-3.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal angioplastyAnkle-brachial indexRadiation therapySFA lesionsRestenosis rateBalloon angioplastyAngiographic binary restenosis rateMean reference vessel diameterSuccessful percutaneous transluminal angioplastySuperficial femoral artery lesionsClinical restenosis rateFeasibility clinical trialBinary restenosis rateClinical adverse eventsReference vessel diameterFemoral artery lesionsMean lesion lengthRate gamma radiationIntravascular radiation therapyMicroSelectron-HDR afterloaderGamma radiation therapyRutherford scoreAdverse eventsArtery lesionsClinical improvement